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After the publication of our paper Dunlop et al. “Rationale and design of the Sodium Lowering In Dialysate (SoLID)
trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for
regression of left ventricular mass”, we became aware of further data correlating left ventricular (LV) mass index at
baseline and their correpsonding mass at 12 months, using cardiac margnetic resonanace imaging (MRI) in patients on
hemodialysis. The original published sample size for the SoLID trial of 118 was a conservative estimate, calculated using
analysis of covariance and a within person Pearson’s correlation for LV mass index of 0.75. New data communicated to
the SoLID trial group has resulted in re-calcuation of the sample size, based upon a within person Pearson’s correlation
of 0.8 but otherwise unchanged assumptions. As a result, the SoLID trial will now recruit 96 participants.Update
After the publication of our paper Dunlop et al. “Rationale
and design of the Sodium Lowering In Dialysate (SoLID)
trial: a randomised controlled trial of low versus standard
dialysate sodium concentration during hemodialysis for
regression of left ventricular mass” [1], we became aware
of further data correlating left ventricular (LV) mass index
at baseline and their correpsonding mass at 12 months,
using cardiac margnetic resonanace imaging (MRI) in pa-
tients on hemodialysis.
The original published sample size for the SoLID trial of
118 was a conservative estimate, calculated using repeated-
measures analysis of covariance (ANCOVA) and a within
person Pearson’s correlation for LV mass index of 0.75.* Correspondence: mrmarsh@woosh.co.nz
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creativecommons.org/publicdomain/zero/1.0/The assumption of a correlation of 0.75 was based on pri-
vate communication from the Jardine group (private com-
munication P Mark 8/2/2011) [2–4]: in a cohort of 59
patients of their patients with repeated measures of LVMI
at least 6 months apart (using cardiac MRI), correlation
was 0.87 (p < 0.001) with normally distributed data. Model-
ling these data, and allowing for 25 % for drop outs, it was
determined that 59 participants would be enrolled in each
arm (power 0.8, alpha 0.05).
New data communicated to the SoLID trial group has
resulted in us re-calculating sample size for the SoLID
trial (private communication C McIntyre and A Odudu
30/4/2014) [5]: in a cohort of 44 patients of their patients
with repeated measures of LV mass index 12 months apart
(using cardiac MRI), correlation was 0.81 (p < 0.001). In 21
of these patients, there was an intervention that might
have modestly affected their LV mass index; however,
restricting analysis to the 23 paired values in the control
group provides a similar correlation of 0.83.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Dunlop et al. BMC Nephrology  (2015) 16:120 Page 2 of 2Based on the data above, the sample size has been
recalculated using a within person correlation of 0.8,
but otherwise unchanged assumptions. It is was deter-
mined that 48 participants will be enrolled in each
arm. The change in sample size has been approved by
the National (New Zealand) Multi-region Ethics Com-
mittee (IRB00004663) of the New Zealand Ministry of
Health (IORG0000895), and the primary funding body
for this study the Health Research Council of New
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